Objective:

Characterize alopecia areata (AA) burden, treatment patterns, and unmet treatment needs among adults in Mexico, overall and by physician-assessed severity.

Approach:

• Design and data: Secondary analysis of linked physician and patient cross-sectional surveys, with retrospective data elements, from the Adelphi Real World AA II Mexico Disease Specific Programme; data were collected October 2024–April 2025.
• Participants and measures: Dermatologists completed records for eight consecutively consulting adults with AA, using severity quotas of three mild, three moderate, and two severe/very severe cases. Patients were invited to complete a separate self-report survey.

Key Findings:

• Disease burden increased with severity; moderate to severe/very severe AA was associated with more extensive scalp and nonscalp hair loss, poorer quality of life, and higher anxiety and depression levels.
• Treatment primarily involved conventional therapies, particularly corticosteroids; advanced therapies were infrequently used, including among patients with severe/very severe AA.
• Patients with severe/very severe AA reported lower treatment satisfaction than those with mild or moderate disease.

Interpretation:

The article reports substantial burden, low treatment satisfaction in severe disease, and limited use of advanced therapies, indicating unmet treatment needs and suggesting potential access and reimbursement barriers in Mexico.

Limitations:

• The supplied context does not report sample size, statistical methods, or detailed study results.
• The cross-sectional survey design captures patient records at one time point and does not establish causal relationships.
• Physician recruitment and prespecified severity quotas may limit how representative the sample is of Mexican adults with AA.

Sources:

• Article context supplied by the user